{"protocolSection":{"identificationModule":{"nctId":"NCT00736476","orgStudyIdInfo":{"id":"V99P2"},"secondaryIdInfos":[{"id":"2007-003511-31"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults","officialTitle":"Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults"},"statusModule":{"statusVerifiedDate":"2016-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-10"},"primaryCompletionDateStruct":{"date":"2010-03","type":"ACTUAL"},"completionDateStruct":{"date":"2010-04","type":"ACTUAL"},"studyFirstSubmitDate":"2008-08-13","studyFirstSubmitQcDate":"2008-08-13","studyFirstPostDateStruct":{"date":"2008-08-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-09-30","resultsFirstSubmitQcDate":"2017-01-09","resultsFirstPostDateStruct":{"date":"2017-02-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-01-09","lastUpdatePostDateStruct":{"date":"2017-02-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Vaccines","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"To study the safety, immunogenicity and efficacy of an investigational H. pylori vaccine, compared with placebo."},"conditionsModule":{"conditions":["Helicobacter Pylori Infection"],"keywords":["helicobacter pylori infection","vaccination","adults"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":63,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: H.pylori vaccines"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo Vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"H.pylori vaccines","description":"1 dose of H.pylori vaccine at 0, 1, and 2 months","armGroupLabels":["1"]},{"type":"BIOLOGICAL","name":"Placebo Vaccine","description":"Placebo Vaccine at 0, 1, and 2 months","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo.","description":"The efficacy of the investigational vaccine to prevent infection following H.pylori challenge in healthy adults was determined in terms of percentage of subjects with positive HP infections in the vaccinated and unvaccinated groups(Placebo).\n\nInfection rates was assessed by invasive Upper Gastrointestinal Endoscopy (UGE)tests that included HP histopathology, HP culture and rapid urease test (RUT), and non-invasive HP tests which included urea breath test (UBT) and fecal antigen test (FAT).","timeFrame":"12 weeks post HP challenge"},{"measure":"Number of Subjects Reporting Solicited Local* and Systemic Adverse Events Following Vaccination","description":"To assess the tolerability of an HP vaccine versus placebo in terms of number of subjects reporting solicited local\\* and systemic adverse events.","timeFrame":"Day 1-7 post vaccination"}],"secondaryOutcomes":[{"measure":"The Time Course of HP Infection Following HP Challenge in Vaccinated and Placebo Groups","description":"The time course of HP infection following HP challenge in subjects of the HP vaccine and placebo groups, were assessed by non-invasive HP tests.","timeFrame":"12 months"},{"measure":"The Geometric Mean Concentrations After HP Vaccination.","description":"The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP)after HP vaccination as compared to placebo are reported.","timeFrame":"upto 1 month after 3rd vaccination"},{"measure":"Geometric Mean Concentrations Against Vaccine Antigens After HP Challenge.","description":"The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP) after HP challenge were compared between vaccinated and placebo groups.","timeFrame":"12 months"},{"measure":"Response on Activated Regulatory T Cell Subset Following HP Vaccination and HP Challenge","description":"The response to 3 doses of HP vaccine and the oral HP challenge was assessed with respect their ability to induce differentiation and changes in the phenotype of a subset of regulatory T-cells CD4+CD25+Foxp3+ that expresses Treg Markers PD-1 and/or HLA-DR.","timeFrame":"12 weeks post HP challenge"},{"measure":"Proliferative Response Against the Pooled H. Pylori Vaccine Antigens by Stimulation Index (SI)","description":"The proliferation of H. pylori-specific Peripheral blood mononuclear cells (PBMCs) following HP antigen stimulation was assessed to measure the magnitude of the cell mediated immune response.","timeFrame":"12 weeks post HP challenge"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adults 18 - 40 years of age in good health\n* HP uninfected\n* not pregnant and agree to use birth control throughout the study (females who can become pregnant)\n\nExclusion Criteria:\n\n* remote or current HP infection","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Vaccines","affiliation":"Novartis Vaccines","role":"STUDY_CHAIR"}],"locations":[{"facility":"Otto von Guericke Universität Magdeburg","city":"Magdeburg","zip":"39120","country":"Germany","geoPoint":{"lat":52.13129,"lon":11.63189}}]},"referencesModule":{"references":[{"pmid":"30042064","type":"DERIVED","citation":"Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2."},{"pmid":"29066327","type":"DERIVED","citation":"Nell S, Estibariz I, Krebes J, Bunk B, Graham DY, Overmann J, Song Y, Sproer C, Yang I, Wex T, Korlach J, Malfertheiner P, Suerbaum S. Genome and Methylome Variation in Helicobacter pylori With a cag Pathogenicity Island During Early Stages of Human Infection. Gastroenterology. 2018 Feb;154(3):612-623.e7. doi: 10.1053/j.gastro.2017.10.014. Epub 2017 Oct 21."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All subjects enrolled were included in the trial.","recruitmentDetails":"Subjects were recruited from a single study center in Germany","groups":[{"id":"FG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of HP Vaccine at 0, 1, and 2 months, followed by H.pylori challenge(oral administration of infectious HP inoculum)1 month later."},{"id":"FG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo at 0, 1, and 2 months,followed by H.pylori challenge (oral administration of infectious HP inoculum)1 month later."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of HP Vaccine at 0, 1, and 2 months."},{"id":"BG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo at 0, 1, and 2 months"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"63"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.6","spread":"5.7"},{"groupId":"BG001","value":"24.0","spread":"3.3"},{"groupId":"BG002","value":"26.1","spread":"5.1"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"33"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"30"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo.","description":"The efficacy of the investigational vaccine to prevent infection following H.pylori challenge in healthy adults was determined in terms of percentage of subjects with positive HP infections in the vaccinated and unvaccinated groups(Placebo).\n\nInfection rates was assessed by invasive Upper Gastrointestinal Endoscopy (UGE)tests that included HP histopathology, HP culture and rapid urease test (RUT), and non-invasive HP tests which included urea breath test (UBT) and fecal antigen test (FAT).","populationDescription":"Per-protocol dataset","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of subjects","timeFrame":"12 weeks post HP challenge","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}]}],"classes":[{"title":"UBT positive (non-invasive test)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"FAT positive (non-invasive test)","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}]}]},{"title":"HP culture positive (invasive test)","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"46"}]}]},{"title":"RUT positive (invasive test)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Histopathology positive (invasive test)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Positive HP infection (Invasive+non-invasive)","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"46"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Solicited Local* and Systemic Adverse Events Following Vaccination","description":"To assess the tolerability of an HP vaccine versus placebo in terms of number of subjects reporting solicited local\\* and systemic adverse events.","populationDescription":"This analysis was done on the safety dataset","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 1-7 post vaccination","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"}]}],"classes":[{"title":"Any Local*","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"23"}]}]},{"title":"Injection site erythema*","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"}]}]},{"title":"Injection site induration*","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Injection site swelling*","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Injection site warmth*","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Injection site tenderness*","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"}]}]},{"title":"Injection site pain*","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"14"}]}]},{"title":"Any Systemic","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"}]}]},{"title":"Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fever (≥38C)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Other#","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Analgesic antipyretic medication used#","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}]},{"title":"Stayed at home due to reaction#","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"The Time Course of HP Infection Following HP Challenge in Vaccinated and Placebo Groups","description":"The time course of HP infection following HP challenge in subjects of the HP vaccine and placebo groups, were assessed by non-invasive HP tests.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"12 months","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}]}],"classes":[{"title":"Baseline (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HP challenge (≥3 months after vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"1 week post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"2 weeks post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"3 weeks post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"4 weeks post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"8 weeks post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"12 weeks post challenge (UBT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Post eradication (UBT positive) (N=7,7)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Baseline (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"1 week post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]},{"title":"2 weeks post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]},{"title":"3 weeks post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]},{"title":"4 weeks post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"8 weeks post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"12 weeks post challenge (FAT positive)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Post eradication (FAT positive) (N=7,7)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"The Geometric Mean Concentrations After HP Vaccination.","description":"The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP)after HP vaccination as compared to placebo are reported.","populationDescription":"Per-Protocol dataset","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"μg/mL","timeFrame":"upto 1 month after 3rd vaccination","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"27"}]}],"classes":[{"title":"Baseline (CagA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"2.42","lowerLimit":"1.78","upperLimit":"3.29"},{"groupId":"OG001","value":"2.95","lowerLimit":"2.09","upperLimit":"4.18"}]}]},{"title":"1 month after 1st vaccination (CagA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"2.89","lowerLimit":"1.87","upperLimit":"4.48"},{"groupId":"OG001","value":"2.55","lowerLimit":"1.55","upperLimit":"4.19"}]}]},{"title":"2 months after 1st vaccination (CagA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"7.74","lowerLimit":"4.83","upperLimit":"12"},{"groupId":"OG001","value":"2.56","lowerLimit":"1.5","upperLimit":"4.39"}]}]},{"title":"3 months after 1st vaccination (CagA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"23","lowerLimit":"15","upperLimit":"37"},{"groupId":"OG001","value":"2.54","lowerLimit":"1.5","upperLimit":"4.29"}]}]},{"title":"Baseline (NAP antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"4.59","lowerLimit":"3.95","upperLimit":"5.33"},{"groupId":"OG001","value":"5.84","lowerLimit":"4.92","upperLimit":"6.93"}]}]},{"title":"1 month after 1st vaccination (NAP antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"35","lowerLimit":"25","upperLimit":"50"},{"groupId":"OG001","value":"5.47","lowerLimit":"3.68","upperLimit":"8.13"}]}]},{"title":"2 months after 1st vaccination (NAP antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"236","lowerLimit":"175","upperLimit":"319"},{"groupId":"OG001","value":"5.15","lowerLimit":"3.66","upperLimit":"7.24"}]}]},{"title":"3 months after 1st vaccination (NAP antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"148","lowerLimit":"111","upperLimit":"197"},{"groupId":"OG001","value":"2.54","lowerLimit":"1.5","upperLimit":"4.29"}]}]},{"title":"Baseline (VacA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"18","lowerLimit":"14","upperLimit":"25"},{"groupId":"OG001","value":"21","lowerLimit":"15","upperLimit":"29"}]}]},{"title":"1 month after 1st vaccination (VacA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"214","lowerLimit":"154","upperLimit":"298"},{"groupId":"OG001","value":"23","lowerLimit":"15","upperLimit":"33"}]}]},{"title":"2 months after 1st vaccination (VacA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"2468","lowerLimit":"1818","upperLimit":"3350"},{"groupId":"OG001","value":"23","lowerLimit":"15","upperLimit":"33"}]}]},{"title":"3 months after 1st vaccination (VacA antigen)","categories":[{"measurements":[{"groupId":"OG000","value":"502","lowerLimit":"335","upperLimit":"709"},{"groupId":"OG001","value":"19","lowerLimit":"13","upperLimit":"28"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations Against Vaccine Antigens After HP Challenge.","description":"The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP) after HP challenge were compared between vaccinated and placebo groups.","populationDescription":"Per-protocol dataset","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"μg/mL","timeFrame":"12 months","groups":[{"id":"OG000","title":"Group I (HP Vaccine) Infected","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."},{"id":"OG001","title":"Group I (HP Vaccine) Non-Infected","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."},{"id":"OG002","title":"Group II (Placebo) Infected","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."},{"id":"OG003","title":"Group II (Placebo) Non-Infected","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"}]}],"classes":[{"title":"Baseline (CagA)","categories":[{"measurements":[{"groupId":"OG000","value":"2.25","lowerLimit":"0.72","upperLimit":"7.02"},{"groupId":"OG001","value":"2.64","lowerLimit":"1.13","upperLimit":"6.16"},{"groupId":"OG002","value":"4.17","lowerLimit":"1.48","upperLimit":"12"},{"groupId":"OG003","value":"3.53","lowerLimit":"1.35","upperLimit":"9.23"}]}]},{"title":"1 month after 1st vaccination(CagA )","categories":[{"measurements":[{"groupId":"OG000","value":"2.24","lowerLimit":"0.42","upperLimit":"12"},{"groupId":"OG001","value":"4.54","lowerLimit":"1.31","upperLimit":"16"},{"groupId":"OG002","value":"3.84","lowerLimit":"0.83","upperLimit":"18"},{"groupId":"OG003","value":"3.06","lowerLimit":"0.74","upperLimit":"13"}]}]},{"title":"2 months after 1st vaccination (CagA )","categories":[{"measurements":[{"groupId":"OG000","value":"2.39","lowerLimit":"0.51","upperLimit":"11"},{"groupId":"OG001","value":"14","lowerLimit":"4.52","upperLimit":"45"},{"groupId":"OG002","value":"4.08","lowerLimit":"1","upperLimit":"17"},{"groupId":"OG003","value":"2.95","lowerLimit":"0.8","upperLimit":"11"}]}]},{"title":"3 months after 1st vaccination (CagA )","categories":[{"measurements":[{"groupId":"OG000","value":"13","lowerLimit":"3.29","upperLimit":"48"},{"groupId":"OG001","value":"93","lowerLimit":"34","upperLimit":"250"},{"groupId":"OG002","value":"3.84","lowerLimit":"1.13","upperLimit":"13"},{"groupId":"OG003","value":"2.63","lowerLimit":"0.85","upperLimit":"8.12"}]}]},{"title":"2 weeks post HP challenge (CagA)","categories":[{"measurements":[{"groupId":"OG000","value":"16","lowerLimit":"4.39","upperLimit":"57"},{"groupId":"OG001","value":"134","lowerLimit":"51","upperLimit":"348"},{"groupId":"OG002","value":"3.92","lowerLimit":"1.22","upperLimit":"13"},{"groupId":"OG003","value":"3.59","lowerLimit":"1.21","upperLimit":"11"}]}]},{"title":"4 weeks post HP challenge (CagA)","categories":[{"measurements":[{"groupId":"OG000","value":"30","lowerLimit":"8.89","upperLimit":"102"},{"groupId":"OG001","value":"261","lowerLimit":"105","upperLimit":"648"},{"groupId":"OG002","value":"4.11","lowerLimit":"1.35","upperLimit":"13"},{"groupId":"OG003","value":"3.39","lowerLimit":"1.21","upperLimit":"9.5"}]}]},{"title":"12 weeks post HP challenge (CagA)","categories":[{"measurements":[{"groupId":"OG000","value":"149","lowerLimit":"35","upperLimit":"625"},{"groupId":"OG001","value":"202","lowerLimit":"69","upperLimit":"588"},{"groupId":"OG002","value":"7.51","lowerLimit":"2.03","upperLimit":"28"},{"groupId":"OG003","value":"4.73","lowerLimit":"1.41","upperLimit":"16"}]}]},{"title":"Baseline (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.75","upperLimit":"7.04"},{"groupId":"OG001","value":"4.4","lowerLimit":"3.1","upperLimit":"6.24"},{"groupId":"OG002","value":"5.46","lowerLimit":"3.56","upperLimit":"8.38"},{"groupId":"OG003","value":"11","lowerLimit":"7.35","upperLimit":"16"}]}]},{"title":"1 month after 1st vaccination (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"19","lowerLimit":"10","upperLimit":"36"},{"groupId":"OG001","value":"62","lowerLimit":"39","upperLimit":"99"},{"groupId":"OG002","value":"5.46","lowerLimit":"3.11","upperLimit":"9.59"},{"groupId":"OG003","value":"8.48","lowerLimit":"5.03","upperLimit":"14"}]}]},{"title":"2 month after 1st vaccination (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"117","lowerLimit":"66","upperLimit":"206"},{"groupId":"OG001","value":"235","lowerLimit":"154","upperLimit":"359"},{"groupId":"OG002","value":"5.54","lowerLimit":"3.3","upperLimit":"9.31"},{"groupId":"OG003","value":"6.61","lowerLimit":"4.09","upperLimit":"11"}]}]},{"title":"3 month after 1st vaccination (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"101","lowerLimit":"60","upperLimit":"172"},{"groupId":"OG001","value":"251","lowerLimit":"170","upperLimit":"373"},{"groupId":"OG002","value":"5.35","lowerLimit":"3.3","upperLimit":"8.66"},{"groupId":"OG003","value":"6.59","lowerLimit":"4.22","upperLimit":"10"}]}]},{"title":"2 weeks post HP challenge (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"125","lowerLimit":"75","upperLimit":"209"},{"groupId":"OG001","value":"275","lowerLimit":"187","upperLimit":"404"},{"groupId":"OG002","value":"5.58","lowerLimit":"3.49","upperLimit":"8.49"},{"groupId":"OG003","value":"8.3","lowerLimit":"5.37","upperLimit":"13"}]}]},{"title":"4 weeks post HP challenge (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"179","lowerLimit":"105","upperLimit":"305"},{"groupId":"OG001","value":"325","lowerLimit":"219","upperLimit":"484"},{"groupId":"OG002","value":"4.4","lowerLimit":"2.7","upperLimit":"7.16"},{"groupId":"OG003","value":"8.32","lowerLimit":"5.3","upperLimit":"13"}]}]},{"title":"12 weeks post HP challenge (NAP)","categories":[{"measurements":[{"groupId":"OG000","value":"115","lowerLimit":"67","upperLimit":"119"},{"groupId":"OG001","value":"208","lowerLimit":"139","upperLimit":"313"},{"groupId":"OG002","value":"4.4","lowerLimit":"2.68","upperLimit":"7.24"},{"groupId":"OG003","value":"8.01","lowerLimit":"5.05","upperLimit":"13"}]}]},{"title":"Baseline (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"21","lowerLimit":"9.26","upperLimit":"47"},{"groupId":"OG001","value":"24","lowerLimit":"13","upperLimit":"44"},{"groupId":"OG002","value":"20","lowerLimit":"9.61","upperLimit":"42"},{"groupId":"OG003","value":"41","lowerLimit":"21","upperLimit":"82"}]}]},{"title":"1 month after 1st vaccination (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"117","lowerLimit":"46","upperLimit":"295"},{"groupId":"OG001","value":"285","lowerLimit":"143","upperLimit":"569"},{"groupId":"OG002","value":"16","lowerLimit":"6.89","upperLimit":"37"},{"groupId":"OG003","value":"33","lowerLimit":"16","upperLimit":"70"}]}]},{"title":"2 months after 1st vaccination (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"1219","lowerLimit":"501","upperLimit":"2966"},{"groupId":"OG001","value":"2754","lowerLimit":"1419","upperLimit":"5344"},{"groupId":"OG002","value":"25","lowerLimit":"11","upperLimit":"56"},{"groupId":"OG003","value":"33","lowerLimit":"16","upperLimit":"70"}]}]},{"title":"3 months after 1st vaccination (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"565","lowerLimit":"247","upperLimit":"1292"},{"groupId":"OG001","value":"979","lowerLimit":"529","upperLimit":"1814"},{"groupId":"OG002","value":"20","lowerLimit":"9.35","upperLimit":"42"},{"groupId":"OG003","value":"34","lowerLimit":"17","upperLimit":"68"}]}]},{"title":"2 weeks post HP challenge (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"606","lowerLimit":"252","upperLimit":"1453"},{"groupId":"OG001","value":"912","lowerLimit":"475","upperLimit":"1751"},{"groupId":"OG002","value":"24","lowerLimit":"11","upperLimit":"53"},{"groupId":"OG003","value":"45","lowerLimit":"22","upperLimit":"94"}]}]},{"title":"4 weeks post HP challenge (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"2174","lowerLimit":"995","upperLimit":"4752"},{"groupId":"OG001","value":"1943","lowerLimit":"1085","upperLimit":"3479"},{"groupId":"OG002","value":"28","lowerLimit":"14","upperLimit":"57"},{"groupId":"OG003","value":"46","lowerLimit":"22","upperLimit":"94"}]}]},{"title":"12 weeks post HP challenge (VacA)","categories":[{"measurements":[{"groupId":"OG000","value":"3467","lowerLimit":"1632","upperLimit":"7366"},{"groupId":"OG001","value":"1469","lowerLimit":"838","upperLimit":"2577"},{"groupId":"OG002","value":"58","lowerLimit":"29","upperLimit":"115"},{"groupId":"OG003","value":"73","lowerLimit":"39","upperLimit":"138"}]}]}]},{"type":"SECONDARY","title":"Response on Activated Regulatory T Cell Subset Following HP Vaccination and HP Challenge","description":"The response to 3 doses of HP vaccine and the oral HP challenge was assessed with respect their ability to induce differentiation and changes in the phenotype of a subset of regulatory T-cells CD4+CD25+Foxp3+ that expresses Treg Markers PD-1 and/or HLA-DR.","populationDescription":"Per-protocol dataset","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of T-cells","timeFrame":"12 weeks post HP challenge","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"15"}]}],"classes":[{"title":"Screening (FOXP3+)","categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.33"},{"groupId":"OG001","value":"1.13","spread":"0.56"}]}]},{"title":"HP challenge (FOXP3+) (N=18,15)","categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.43"},{"groupId":"OG001","value":"1.07","spread":"0.48"}]}]},{"title":"2 weeks post challenge (FOXP3+) (N=15,14)","categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.38"},{"groupId":"OG001","value":"1.31","spread":"0.57"}]}]},{"title":"12 weeks post challenge (FOXP3+)(N=10,9)","categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.45"},{"groupId":"OG001","value":"0.87","spread":"0.48"}]}]},{"title":"Screening (HLADR TOT)","categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"8.22"},{"groupId":"OG001","value":"22","spread":"10"}]}]},{"title":"HP challenge (HLADR TOT) (N=18,15)","categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":"8.36"},{"groupId":"OG001","value":"24","spread":"11"}]}]},{"title":"2 weeks post challenge (HLADR TOT) (N=15,14)","categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":"8.36"},{"groupId":"OG001","value":"21","spread":"8.44"}]}]},{"title":"12 weeks post challenge (HLADR TOT) (N=10,9)","categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"7.95"},{"groupId":"OG001","value":"23","spread":"11"}]}]},{"title":"Screening (PD-1 TOT)","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"2.55"},{"groupId":"OG001","value":"5.22","spread":"2.06"}]}]},{"title":"HP challenge (PD-1 TOT) (N=18,15)","categories":[{"measurements":[{"groupId":"OG000","value":"5.69","spread":"1.93"},{"groupId":"OG001","value":"5.4","spread":"2.74"}]}]},{"title":"2 weeks post challenge (PD-1 TOT) (N=15,14)","categories":[{"measurements":[{"groupId":"OG000","value":"6.12","spread":"2.38"},{"groupId":"OG001","value":"5.79","spread":"2.52"}]}]},{"title":"12 weeks post challenge (PD-1 TOT) (N=10,9)","categories":[{"measurements":[{"groupId":"OG000","value":"4.33","spread":"1.31"},{"groupId":"OG001","value":"5.53","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Proliferative Response Against the Pooled H. Pylori Vaccine Antigens by Stimulation Index (SI)","description":"The proliferation of H. pylori-specific Peripheral blood mononuclear cells (PBMCs) following HP antigen stimulation was assessed to measure the magnitude of the cell mediated immune response.","populationDescription":"Per-protocol dataset","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Stimulation Index (SI)","timeFrame":"12 weeks post HP challenge","groups":[{"id":"OG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."},{"id":"OG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"16"}]}],"classes":[{"title":"Screening","categories":[{"measurements":[{"groupId":"OG000","value":"6.85","spread":"6.05"},{"groupId":"OG001","value":"3.69","spread":"3.7"}]}]},{"title":"HP challenge (N=21,16)","categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":"21"},{"groupId":"OG001","value":"3.81","spread":"2.61"}]}]},{"title":"2 weeks post challenge (N=17,13)","categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":"37"},{"groupId":"OG001","value":"24","spread":"19"}]}]},{"title":"12 weeks post challenge (N=13,12)","categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":"23"},{"groupId":"OG001","value":"7.83","spread":"2.82"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Throughout the study period (12-14 months)","eventGroups":[{"id":"EG000","title":"Group I (HP Vaccine)","description":"Subjects received three injections of HP Vaccine at 0, 1, and 2 months.","seriousNumAffected":1,"seriousNumAtRisk":36,"otherNumAffected":33,"otherNumAtRisk":36},{"id":"EG001","title":"Group II (Placebo)","description":"Subjects received three injections of Placebo at 0, 1, and 2 months","seriousNumAffected":0,"seriousNumAtRisk":27,"otherNumAffected":25,"otherNumAtRisk":27}],"seriousEvents":[{"term":"Pilonidal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]}],"otherEvents":[{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":36},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":27}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":36},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":27}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":36},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":27}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":28,"numAtRisk":36},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":27}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":27}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":36},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":27}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":36},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":27}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Posting Director","organization":"Novartis Vaccines and Diagnostics","email":"RegistryContactVaccinesUS@novartis.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}